Global Contraceptives Industry

NEW YORK, March 19, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Contraceptives Industry

http://www.reportlinker.com/p087292/Global-Contraceptives-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

This report analyzes the worldwide markets for Contraceptives in US$ Million by the following Product Segments: Oral Contraceptives, Condoms, Implants/ Injections, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. A six-year historic analysis is also provided for these markets. The report profiles 123 companies including many key and niche players such as Ansell Limited, Condomi Health International GmbH, Bayer HealthCare Pharmaceuticals, Church & Dwight Co. Inc., Conceptus, Inc., Female Health Company, Fuji Latex Co Ltd., HLL Lifecare Limited, Johnson & Johnson, Janssen Pharmaceuticals Inc., Merck & Co., Inc., Okamoto Industries, Inc., Reckitt Benckiser Group Plc, Teva Pharmaceutical Industries Limited, Warner Chilcott plc, and Pfizer Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-2Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-3Oral Contraceptives I-3Condoms I-3Implants/Injections I-4Other Contraceptives I-4II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

A Primer II-1

Contraceptives Market: Quick Facts II-2

Outlook II-2

Growth Drivers II-2

Challenges II-3

Impact of Recession: An Unequivocal Review II-3

Cooling Economy Induces Changes in Childbearing Trends II-3

Recession Adds Fuel to Cost/Affordability Challenge II-4

Rising Preference for Surgical Family Planning Procedures II-4

Contraceptives among Women: Scenario in the Developing World II-4

Table 1: Contraceptives Market in Developing World (2012):

Percentage Breakdown of Unintended Pregnancies by

Contraceptive Usage Trend (includes corresponding

Graph/Chart) II-5

Table 2: Capability of Modern Contraception in MitigatingMortality by Unintended Pregnancies in Developing Countries(2012) (includes corresponding Graph/Chart) II-5Other Trends & Issues II-5Consolidation to Guide New Entrants into the ContraceptivesMarket II-5Increasing Awareness Over STDs to Create Additional Demandfor Condoms II-6HIV Prevalence and Incidence Statistics II-6Table 3: Global Prevalence of HIV Infection in 2010 byRegion (in Millions) (includes corresponding Graph/Chart) II-7

Table 4: Newly Infected HIV Population in 2010 by Region

(in Millions) (includes corresponding Graph/Chart) II-8

Table 5: Global HIV Related Deaths in 2010 by Region inMillions (includes corresponding Graph/Chart) II-9

Table 6: Global HIV Prevalence among Adults and Youth (Male

and Female) By Region: 2010 II-10

Multifunctional Modern Contraceptives Make a Foray II-10

Skin Sprays: A Novel Way of Contraception II-10

Extensive Distribution Drives growth of Contraceptive Products II-11

Public Health Organizations Spur Condoms Use II-11

USAID Worldwide Shipments of Condoms and Other Contraceptives II-12

Table 7: USAID Shipments of Condoms and Contraceptives

Worldwide (2011): Percentage Share Breakdown of Unit

Shipments by Type - Male Condoms, Female Condoms and Oral

Contraceptives II-12

Table 8: USAID Shipments of Condoms and Other ContraceptivesWorldwide (2010): Percentage Share Breakdown of ValueShipments by Region -Africa, Asia/Near East, Caribbean/LatinAmerica and Europe/Eurasia (includes correspondingGraph/Chart) II-12

Table 9: Global USAID Shipments of Condoms and Other

Contraceptives (2010): Percentage Share Breakdown of Value

Shipments by Type -Condoms, Injectables, Orals, Implants and

IUDs (includes corresponding Graph/Chart) II-13

Table 10: USAID Shipments of Condoms and OtherContraceptives Worldwide (2010): Percentage Share Breakdownof Value Shipments by Program Type -Parastatal/Governmental,Social Marketing, NGO and Research (includes correspondingGraph/Chart) II-13Latex Supply Woes Impact the Condoms Market II-13Advertising for Contraceptives Acquires A Whole New Dimension II-14Emergency Contraception Receives Encouragement from Government II-14Manufacturers & Retailers Work in Sync to Accelerate Sales II-15Competition in the Contraceptives R&D Market to Intensify II-15Table 11: Global Contraceptives Market (2010): PercentageBreakdown of Product Share in the R&D Pipeline by Stage ofClinical Trial (includes corresponding Graph/Chart) II-15Innovation Keeps the Fire Burning for the Condoms Market II-16Generic & Biosimilar Contraceptive Products Gain Ground II-16Generics Manufacturers II-16OTC Hormonal Contraceptives - An Attractive Market II-16Oral Contraceptives - A Painless Panacea for Prevention ofUnwanted Pregnancy II-17R&D Companies & Generic Manufacturers - Developing Countries II-17Commercial Success of R&D Brands Sustain DevelopmentalPrograms in Developing Countries II-18Challenges Facing Generic Contraceptive Products Manufacturers II-18

2. PRODUCT OVERVIEW II-19

Types of Contraception II-19

The Contraceptive Timeline II-19

By Function II-20

Barrier Contraceptives II-20

Characteristic Features of Barrier Methods II-20

Hormonal Contraceptives II-21

Prescription Contraceptives II-21

Oral Contraceptives II-21

Overview of Oral Contraceptives - Benefits vs. Risks II-21

Usage Levels of OCs in Worldwide Scenario II-22

Traditional and Modern II-22

Reversible and Permanent II-22

Birth Control Methods and their Use in Major Regions

Worldwide II-23

Contraception - Levels of Effectiveness II-24

Effectiveness Index of Contraceptive Measures II-24

Unmet Need for Contraception II-27

Segmental Analysis II-27

A. Condoms II-27

Overview II-27

Categories II-27

Latex Condoms II-27

Non-Latex Condoms II-27

Skin Condoms II-28

Polyurethane (PU) Condoms II-28

Comparison Between Polyurethane & Latex Condoms II-28

Male Condom - Effectiveness of Protection Against STDs II-29

Myths & Facts II-29

Selection & Effective Use of Condoms II-29

Highlights II-30

Growth Factors II-30

Factors Hindering Wide Spread Use of Condoms II-30

Measures Aimed at Increasing Usage II-31

Female Condoms II-31

Who are the Main Users? II-31

Reality - An Effective Female Condom II-32

B. Oral Contraceptives (OCs)/Pills II-32

A Peep into the Past II-32

Synthetic Oral Contraceptives II-33

Characteristic Features of Oral Contraceptives (OCs) II-33

Bayer Schering Pharma's "Yasmin": A Resounding Brand

Worldwide II-33

Advantages of Using OCs II-34

Effects of Long-Term Use of OCs II-34

Use of OCs/Pills - Myths & Facts II-35

Oral Contraceptives - Challenges & Strategies to Overcome

Problems II-35

Factors Associated with Failure of OCs/Pills II-36

Health Conditions to be Addressed when Using OCs II-36

Understanding Risks Associated with Use of OCs II-36

Cardiovascular Disease - A Major Side Effect of OCs II-37

Intake of OCs Result in High Blood Pressure II-37

Smoking Intensifies Respiratory Problems in Pill Users II-37

Age Related Complications Associated with the Direct Use

of OCs II-37

Relation Between OC and Cancer II-37

Depression Linked to Use of OCs II-38

OCs Increases Osteoporosis Risk at Later Stage II-38

OCs May Reduce Sex Drive II-38

Effects of Pill on Childbearing Capacity II-38

Visiting a Doctor - Highly Recommended in Case of Warning

Symptoms II-39

Emergency Contraception (EC) - A New Face of OCs II-39

Role of ECPs II-39

Effectiveness of ECP II-39

Different Types of EC Products II-40

Mini Pills II-40

RU486 - the French Abortion Pill II-41

Availability of Hormonal Contraceptives as OTC Drugs II-41

C. Injectable Contraceptives II-41

Depo-Provera II-41

Characteristic Features of Injectable Contraceptives II-42

Injectables - Challenges & Strategies to Overcome Problems II-42

D. Intrauterine Devices (IUDs)/Implants II-43

Product Categories II-43

CopperT 380A (ParaGard) II-43

Progesterone T (or Progestasert) II-43

Characteristic Features II-44

Benefits II-44

Side Effects II-44

Challenges & Strategies to Overcome Problems II-45

Long-term Reversible Contraceptive Implants II-45

Products II-45

Norplant II-45

Implanon II-46

Mirena II-46

Characteristic Features of Implantable Contraceptives II-46

Challenges & Strategies to Overcome Problems II-47

E. Spermicides II-47

Product Categories II-48

Benefits II-48

Drawbacks II-48

Contraceptive Foam II-48

Delfen Contraceptive Foam II-48

Contraceptive Cream or Jelly II-48

Encare Ovals II-48

Table 12: Effectiveness in Prevention of Pregnancy -

Condom and Spermicide, Condom Alone and Spermicide Alone

(includes corresponding Graph/Chart) II-49

F. Diaphragms II-49

G. Withdrawal & Douching II-50

H. Sterilization II-50

Tubal Ligation II-51

Reasons Behind Adoption II-51

Risk of Complications II-51

Types II-51

Abdominal Procedures II-52

Laparoscopy II-52

Mini-Laparotomy II-52

Laparotomy II-52

Vaginal Procedures II-52

Culdoscopy II-52

Colpotomy II-52

Hysterectomy - A High Risk Surgery II-53

Selective Tubal Occlusion Procedure (STOP) II-53

Vasectomy II-53

Method of Working II-53

Reasons Behind Adoption II-54

Risk of Complications II-54

I. Other Contraceptive Methods II-54

Contraceptive Sponges II-54

Today Sponge II-55

Characteristic Features of Today Sponge II-55

Table 13: Efficiency Rates of Today Sponge Based on

Usage for 12-Month Period (includes corresponding

Graph/Chart) II-56

Protectaid Sponge II-56

Characteristic Features of Protectaid Sponge II-57

Cervical Caps II-57

Pros and Cons of the Device II-57

Vaginal Contraceptive Film (VCF) II-58

Contraceptive Vaccine II-58

Ortho Evra Weekly Contraceptive Patch II-58

NuvaRing Monthly Vaginal Ring II-58

3. RESEARCH AND DEVELOPMENT II-59Oral Contraceptive Minimizes Premenstrual Syndrome Symptomsas per New Study II-59Cause of Infertility - Not Associated with IUDs II-59Presence of Estrogen in OCs Offers Protection from ColorectalCancer II-60Hormonal Contraceptive Usage & Risk Associated with Certain STDs II-60Use of Third Generation Ocs Increases Risk of Blood Clots II-60High Risk of Deep Vein Thrombosis with Cyproterone-Containing OCs II-60

4. ROLE OF UNITED NATIONS IN PROMOTING USE OF CONTRACEPTIVES II-61

Female Condoms Reach New Heights with Aid from UNAIDS II-61

Donor Support for Contraceptive Commodity II-61

Table 14: Total Cost of Contraceptives and Condoms:

2000-2010 (In US$ Million) (includes corresponding

Graph/Chart) II-61

Unmet Need II-62

Urgent Need for Use of Modern Contraceptives II-62

Table 15: Penetration of Modern Contraceptives in Developing

Regions for Women in Reproductive Age by Need (2011)

(includes corresponding Graph/Chart) II-62

Table 16: Usage of Modern Contraceptive by Women inDeveloping Countries (2012): Percentage Breakdown by Type(includes corresponding Graph/Chart) II-63Use of Modern Contraceptives Grows in Developing Regions II-63Table 17: Estimated Numbers of Contraceptive Users inDeveloping Nations: 2000-2015 (In Millions) (includescorresponding Graph/Chart) II-63

Table 18: Percentage Penetration of Modern Contraceptives by

Married Women by Region/ Country (2011) (includes

corresponding Graph/Chart) II-64

Table 19: Capability of Modern Contraception in MitigatingMortality by Unintended Pregnancies in Developing Countries(2012) (includes corresponding Graph/Chart) II-64Difference in Usage of Oral contraceptives in Developed andDeveloping World II-65Prevalence of Contraceptive Methods II-65Table 20: Worldwide Contraceptives Market: Estimated Numberof Users (2015 & 2025) - Asia, Latin America and Africa (InMillions) (includes corresponding Graph/Chart) II-65

Table 21: Worldwide Contraceptive Market: Prevalence in

Women (2000-2025) - Percentage Share by Asia, Latin America

and Africa (includes corresponding Graph/Chart) II-66

United Nations Population Fund (UNFPA) II-66

UNFPA Gets Aid from Britain to Help Developing World II-67

Rise in Cost of Providing Contraceptives II-68

Future Trends Worldwide II-68

5. NEW PRODUCT INTRODUCTIONS/ INNOVATIONS II-69Watson Pharmaceuticals Introduces Vestura an Oral Contraceptive II-69Ansell Unveils SKYN® Condom in Brazil and China II-69Vystar® and Ritex Gummiwarenfabrik to Launch Ritex Silver-Light Condoms II-69Bayer HealthCare Pharmaceuticals Introduces Qlaira® OralContraceptive II-69The Female Health Offers La Luna Female Condoms in Israel II-69Merck & Co Introduces NEXPLANON 68mg II-70Watson Pharmaceuticals Introduces Generess™ Fe II-70WomanCare Global Includes Essure® to Product Portfolio II-70LifeStyles Introduces SKYN® Large II-70Acme Brasil Introduces Condoms under the Unique by NaturalSensation® II-71Conceptus Launches Essure FlexPayTM Financial Assistance Plan II-71Lupin Pharmaceuticals Introduces Generic Femcon Fe ChewableTablets in US II-71Hyundai Pharm and HRA Pharma Roll Out ellaOne in South Korea II-71Futura Develops CSD500 II-72

6. PRODUCT INNOVATIONS/INTRODUCTIONS IN THE RECENT PAST - A

PERSPECTIVE BUILDER II-73

Watson Pharmaceuticals Rolls Out ella Oral Emergency

Contraceptive II-73

HLL Lifecare to Launch Pan Flavoured Condoms II-73

Glenmark Generics Receives USFDA Approval for Norethindrone

Tablets II-73

HLL Lifecare to Introduce Moods in Australian Markets II-73

Organon Releases Contraceptive NuvaRing II-74

HRA Pharma Unveils ellaOne II-74

Bayer Introduces Qlaira New Oral Contraceptive II-74

Durex Introduces Avanti Bare™ II-74

Teva to Introduce Tri-Lo Sprintec II-74

Teva Announces Launch of Topiramate Tablets II-74

Duramed Releases LoSEASONIQUE II-75

Uganda Health Marketing Group Rolls Out NewFem, A New

Contraceptive Pill II-75

TTK LIG to Unveil Durex Jeans Condoms II-75

Teva Pharmaceutical Industries Receives Approval for Plan B

One-Step Emergency Contraceptive II-75

Cupid Limited to Unveil Cost-effective Female Condoms II-76

Bayer Schering Pharma Launches Qlaira® II-76

Watson Laboratories Secures USFDA Approval for Plan B OTC

Generics II-76

Organon Launches Vaginal Contraceptive Ring II-76

7. RECENT INDUSTRY ACTIVITY II-77Ansell Takes Over Trelleborg Protective Products Operations II-77Bayer HealthCare Partners with USAID to Launch Microgynon FeContraceptive II-77DKT International to Distribute Contraceptives in Ghana II-77Conceptus Obtains FDA Approval for Inclusion of 10-Year Datafor Essure® Procedure II-77Conceptus Secures FDA Approval for Label Changes Related toCompatible Usage of NovaSure® with Essure II-78Lupin Receives FDA Approval for Generic Variant of Ortho Tri-cyclen Lo Oral Contraceptive II-78Glenmark Generics US Receives FDA Approval for EthinylEstradiol and Norgestimate Tablets II-78Bayer HealthCare Pharmaceuticals Receives FDA Approval forNataziaTM II-79Teva Receives FDA Approval for Quartette™, An OralContraceptive for Females II-79Agile Therapeutics Receives FDA Approval for AG200-15,Contraceptive Patch II-79The Female Health Company Established Two New ProductionLines In Malaysia II-79Glenmark Receives Approval for its Viorele, an OralContraceptive for Women II-79Watson Pharmaceuticals Receives USFDA Approval for Beyaz II-80Bayer Files for EU Approval for the Company's Birth ControlPatch II-80J&J 's Ortho Evra, Birth Control Patch Receives FDA Approval II-80Pfizer Recalls Norgestrel/Ethinyl Estradiol Tablets and Lo/Ovral®-28 Tablets from US II-80Savanna East Africa Acquires Kenyan Condom Producer in Kenya II-81Ansell Takes Over Minority Stake in Yulex II-81Ortho-McNeil and PriCara to Operate Under JanssenPharmaceuticals II-81Conceptus Acquires Distribution Rights to Essure Device II-81Sosei Receives Approval for NorLevo Tablets by Japan Ministryof Health, Labour and Welfare II-82Starpharma Holdings Inks Licensing Agreement with Ansell II-82Starpharma Holdings Enters into Agreement with Okamoto II-82Female Health Company Receives Supply Order from BritishGovernment II-82

8. CORPORATE ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER II-83

WomanCare Global Acquires Roselle and Optinor from Icon II-83

Teva Signs Deal to Acquire Theramax II-83

Ferring Pharmaceuticals Purchases Lysteda from Xanodyne

Pharmaceuticals II-83

NextPharma Technologies Expands Waltrop Semi-Solids Hormones

Facility II-84

Reckitt Benckiser Acquires SSL International II-84

Warner Chilcott and Lupin Pharmaceuticals Ink Settlement

Agreement II-84

FHC Bags Order to Supply 3.5 Million FC2 Female Condoms for

2010 World Cup in South Africa II-84

SSL Acquires Majority Stake in BLBV II-85

Columbia Laboratories Inks Definitive Agreement with Watson

Pharmaceuticals II-85

Piramal Healthcare Signs Definitive Agreement with Cipla II-85

Watson Pharmaceuticals to Market HRA Pharma's Emergency

Contraceptive II-86

Lupin to Establish Three New Production Facilities II-86

Pfizer to Purchase Wyeth II-86

Ansell Healthcare Signs Agreement with NYC Department of

Health and Mental Hygiene II-86

Teva Pharmaceutical Industries' Yaz Receives FDA Approval II-87

Teva Pharmaceutical Industries' Yaz Receives Marketing

Approval from FDA II-87

Watson Pharmaceuticals, Warner Chilcott Collaborate for Femring II-87

Watson Pharmaceuticals Inks Agreement with Warner Chilcott

for WC3026 II-87

Merck Merges with Schering-Plough II-88

Vystar Inks Agreement with Centrotrade Minerals and Metals

and Centrotrade Deutschland II-88

Mayer Laboratories Signs Agreement with Alvogen Group II-88

Hypermarcas Acquires Inal II-88

Sosei Inks Distribution Agreement with ASKA Pharmaceuticals II-88

Sanofi-Aventis to Construct Plant in Brazil II-89

Durex Chinese Plant Starts Production II-89

Patheon Expands Toronto Plant II-89

Female Health Co Receives FDA Approval for Cheaper Female Condom II-89

9. FOCUS ON SELECT GLOBAL PLAYERS II-90Ansell Limited (Australia) II-90Condomi Health International GmbH (Germany) II-90Bayer HealthCare Pharmaceuticals (Germany) II-90Church & Dwight Co., Inc. (US) II-91Conceptus Inc (US) II-91Female Health Company (US) II-91Fuji Latex Co Ltd (Japan) II-92HLL Lifecare Limited (India) II-92Johnson & Johnson (US) II-93Janssen Pharmaceuticals Inc. (US) II-93Merck & Co., Inc (USA) II-93Okamoto Industries Inc (Japan) II-94Reckitt Benckiser Group Plc (UK) II-94Teva Pharmaceutical Industries Limited (Israel) II-94Warner Chilcott plc (Ireland) II-95Pfizer Inc (USA) II-95

10. GLOBAL MARKET PERSPECTIVE II-96

Table 22: World Recent Past, Current & Future Analysis for

Contraceptives by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Latin America and Rest

of World Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2010 through 2018 (includes

corresponding Graph/Chart) II-96

Table 23: World Historic Review for Contraceptives byGeographic Region - US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), Latin America and Rest of World MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2004 through 2009 (includes correspondingGraph/Chart) II-97

Table 24: World 15-Year Perspective for Contraceptives by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Latin America and Rest of World Markets for Years 2004, 2011

& 2018 (includes corresponding Graph/Chart) II-98

Table 25: World Recent Past, Current & Future Analysis forOral Contraceptives by Geographic Region - US, Canada, Japan,Europe, Asia-Pacific (excluding Japan), Latin America andRest of World Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2010 through 2018 (includescorresponding Graph/Chart) II-99

Table 26: World Historic Review for Oral Contraceptives by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2004 through 2009 (includes corresponding

Graph/Chart) II-100

Table 27: World 15-Year Perspective for Oral Contraceptives byGeographic Region - Percentage Breakdown of Dollar Sales forUS, Canada, Japan, Europe, Asia-Pacific (excluding Japan),Latin America and Rest of World Markets for Years 2004, 2011& 2018 (includes corresponding Graph/Chart) II-101

Table 28: World Recent Past, Current & Future Analysis for

Condoms by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Latin America and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2010 through 2018 (includes

corresponding Graph/Chart) II-102

Table 29: World Historic Review for Condoms by GeographicRegion - US, Canada, Japan, Europe, Asia-Pacific (excludingJapan), Latin America and Rest of World Markets IndependentlyAnalyzed with Annual Sales Figures in US$ Million for Years2004 through 2009 (includes corresponding Graph/Chart) II-103

Table 30: World 15-Year Perspective for Condoms by Geographic

Region - Percentage Breakdown of Dollar Sales for US, Canada,

Japan, Europe, Asia-Pacific (excluding Japan), Latin America

and Rest of World Markets for Years 2004, 2011 & 2018

(includes corresponding Graph/Chart) II-104

Table 31: World Recent Past, Current & Future Analysis forImplants/Injections by Geographic Region - US, Canada, Japan,Europe, Asia-Pacific (excluding Japan), Latin America andRest of World Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2010 through 2018 (includescorresponding Graph/Chart) II-105

Table 32: World Historic Review for Implants/Injections by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2004 through 2009 (includes corresponding

Graph/Chart) II-106

Table 33: World 15-Year Perspective for Implants/ Injectionsby Geographic Region - Percentage Breakdown of Dollar Salesfor US, Canada, Japan, Europe, Asia-Pacific (excludingJapan), Latin America and Rest of World Markets for Years2004, 2011 & 2018 (includes corresponding Graph/Chart) II-107

Table 34: World Recent Past, Current & Future Analysis for

Other Contraceptives by Geographic Region - US, Canada,

Japan, Europe, Asia-Pacific (excluding Japan), Latin America

and Rest of World Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2010 through 2018

(includes corresponding Graph/Chart) II-108

Table 35: World Historic Review for Other Contraceptives byGeographic Region - US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), Latin America and Rest of World MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2004 through 2009 (includes correspondingGraph/Chart) II-109

Table 36: World 15-Year Perspective for Other Contraceptives

by Geographic Region - Percentage Breakdown of Dollar Sales

for US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), Latin America and Rest of World Markets for Years

2004, 2011 & 2018 (includes corresponding Graph/Chart) II-110

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Outlook III-1

Restraints III-1

Are Women's Reproductive Rights Getting Axed on the New

Health Care Bill? III-1

Medicaid Coverage For Family Planning III-2

Regulations Encouraging Access to Emergency Contraceptives III-2

Major Market Trends III-3

Generics Pitted Against Branded in the Oral Contraceptives

Market III-3

Changing Consumer Demographics III-3

Relentless Promotional Programs Drive Home the Point III-3

Use of Intimacy Products on the Rise III-4

Generics Ransack the Branded Market III-4

Condoms - A 'Fun, Inviting and Pleasurable' Way to Healthy

Life and Lifestyle III-4

Market Share Statistics III-5

Table 37: Leading Players in the US Male Contraceptives

Market (2011): Percentage Breakdown of Sales for Church and

Dwight Co., Reckitt Benckiser, Ansell, Global Protection,

Mayer Labs, Majestic Drug Co., Private label and Others

(includes corresponding Graph/Chart) III-5

Table 38: US Market for Condoms by Leading Players (2011):Market Share Breakdown for Church & Dwight, ReckittBenckiser, Ansell America, and Others (includescorresponding Graph/Chart) III-5

Table 39: Leading Brands in the US Condom Market (2011):

Percentage Share Breakdown by Sales (includes

corresponding Graph/Chart) III-6

Table 40: US Condoms Market: Percentage Breakdown of DollarSales by Product Type for the Year Ended January 2006(includes corresponding Graph/Chart) III-6

Table 41: Leading Female Contraceptive Manufacturers in the

US (2011): Percentage Breakdown of Market Share for Duramed

Pharmaceuticals, Watson Pharmaceuticals, Coldwell Consumer

Health, Apothecus and Others (includes corresponding

Graph/Chart) III-6

Table 42: Leading Brands in the Female ContraceptivesMarket in the US (2009): Percentage Breakdown of MarketShare for Plan B, VCF, Ortho Options Conceptrol, Encare,Ortho Options Gynol II and Others (includes correspondingGraph/Chart) III-7Noticeable Shift in Retail Marketing Techniques III-7Rising Use of Condoms Amongst Teenagers III-7Changing Attitudes and Perceptions Drive Market Sales III-8Table 43: Contraceptive Usage (Methods) and Non-Usageamong Women Aged 15-44 Years in the US (2011) (includescorresponding Graph/Chart) III-8Elimination of Co-pays to Boost Contraceptive Sales III-9Pill Continues to be One of the Most Popular Forms ofContraception III-9Table 44: Usage Trends of Select Contraceptive MethodsAmong Women Aged 15-44 Years in the US (2011): PercentageBreakdown by Marital Status (includes correspondingGraph/Chart) III-10

Table 45: Female Contraception in the US (2011): Percentage

Breakdown of Usage of Pill or Sterilization Method by Age

Group (includes corresponding Graph/Chart) III-10

Table 46: Leading Birth Control Pill Brands in the US(2011): Percentage Breakdown of Market Share for Yaz,Tri-Sprintec, Ocella, Loestrin 24 Fe, NuvaRing, Sprintec,Trinessa, Aviane, Ortho Tri-Cyclen Lo and Others(includes corresponding Graph/Chart) III-11Oral Contraceptives Gain Ground in the US III-11Table 47: Leading Birth Control Pill Manufacturers in theUS (2010): Percentage Breakdown of Market Share for DuramedPharmaceuticals, Watson Pharmaceuticals Inc., CaldwellConsumer Health L.L.C., Apothecus Inc. and Others(includes corresponding Graph/Chart) III-11Oral Contraceptives and its Shades of Grey III-12Marketing Efforts Aimed at Influencing Female CollegeStudents III-12Condoms Continuing Canter III-12Drug Stores Remain the Choice for Contraceptive Needs III-12Trade Class Statistics III-13Oral Contraceptives - Unanimously the Choice of American Women III-13Table 48: Contraceptive Features Preferred by Women in US(includes corresponding Graph/Chart) III-13Health Facts III-14Rising Use of Oral Contraceptives III-14Abortion Control Drugs & Methods III-14Medical Abortion III-15a. Mifepristone - A Medical Breakthrough III-15b. Methotrexate III-15Expanding the Use & Availability of EC Drugs III-15Pharmacies Sell ECPs III-15Demographics III-16Facts and Figures III-16Sales of Contraceptives (Male & Female) - Family PlanningCategory III-16Insurance Coverage for Contraceptives Still in Contest III-16Strategic Corporate Developments III-17Product Innovations/Launches III-19Key Players III-21B.Market Analytics III-25Table 49: US Recent Past, Current & Future Analysis forContraceptives by Product Segment - Oral Contraceptives,Condoms, Implants/Injections and Others MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-25

Table 50: US Historic Review for Contraceptives by Product

Segment - Oral Contraceptives, Condoms, Implants/Injections

and Others Markets Segments Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2004 through

2009 (includes corresponding Graph/Chart) III-26

Table 51: US 15-Year Perspective for Contraceptives byProduct Segment - Percentage Breakdown of Dollar Sales forOral Contraceptives, Condoms, Implants/Injections and OthersMarkets for 2004, 2011 & 2018 (includes correspondingGraph/Chart) III-27

2. CANADA III-28

A.Market Analysis III-28

Scenario III-28

Outlook III-28

Condoms Market III-28

Immucon Obtains US Patent for Male Contraceptive Technology III-28

B.Market Analytics III-29

Table 52: Canadian Recent Past, Current & Future Analysis

for Contraceptives by Product Segment - Oral

Contraceptives, Condoms, Implants/Injections and Others

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2010 through 2018 (includes

corresponding Graph/Chart) III-29

Table 53: Canada Historic Review for Contraceptives byProduct Segment - Oral Contraceptives, Condoms,Implants/Injections and Others Markets SegmentsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2004 through 2009 (includes correspondingGraph/Chart) III-30

Table 54: Canadian 15-Year Perspective for Contraceptives by

Product Segment - Percentage Breakdown of Dollar Sales Oral

Contraceptives, Condoms, Implants/Injections and Others

Markets for 2004, 2011 & 2018 (includes corresponding

Graph/Chart) III-31

3. JAPAN III-32A.Market Analysis III-32Outlook III-32Market for Oral Contraceptives Yet to Take Off III-32Innovation Expected to Drive Sales III-32Major Issues and Trends III-32Domestic Products Dominate the Market III-32Health Care Institutions Remain Main Distribution Channels III-33Market Issues III-33Compulsory Labeling of Contraceptives III-33Impact of Legalization of Oral Contraceptives III-33Late Approval for Use of OCs in Japan III-33Factors Hindering Widespread Use of OCs III-34Condoms Market III-34Key Players III-34B.Market Analytics III-36Table 55: Japanese Recent Past, Current & Future Analysisfor Contraceptives by Product Segment - OralContraceptives, Condoms, Implants/Injections and OthersMarkets Independently Analyzed with Annual Sales Figures inUS$ Million for Years 2010 through 2018 (includescorresponding Graph/Chart) III-36

Table 56: Japanese Historic Review for Contraceptives by

Product Segment - Oral Contraceptives, Condoms,

Implants/Injections and Others Markets Segments

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2004 through 2009 (includes corresponding

Graph/Chart) III-37

Table 57: Japanese 15-Year Perspective for Contraceptives byProduct Segment - Percentage Breakdown of Dollar Sales forOral Contraceptives, Condoms, Implants/Injections and OthersMarkets for 2004, 2011 & 2018 (includes correspondingGraph/Chart) III-38

4. EUROPE III-39

A.Market Analysis III-39

Outlook III-39

Condoms Market III-39

Prejudices Pertaining to Birth Control Pills III-39

Condoms and Other Contraceptives Market III-39

Table 58: USAID Shipments of Condoms and Other

Contraceptives to Europe and Eurasia (2010): Percentage

Share Breakdown of Value Shipments by Type -Condoms,

Orals, Female Condoms, IUDs and Injectables (includes

corresponding Graph/Chart) III-39

B.Market Analytics III-40

Table 59: European Recent Past, Current & Future Analysis

for Contraceptives by Geographic Region - France, Germany,

Italy, UK, Spain, Russia and Rest of Europe Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2010 through 2018 (includes corresponding

Graph/Chart) III-40

Table 60: European Historic Review for Contraceptives byContraceptives by Geographic Region - France, Germany,Italy, UK, Spain, Russia and Rest of Europe MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2004 through 2009 (includescorresponding Graph/Chart) III-41

Table 61: European 15-Year Perspective for Contraceptives by

Geographic Region - Percentage Breakdown of Dollar Sales

for France, Germany, Italy, UK, Spain, Russia and Rest of

Europe Markets for Years 2004, 2011 & 2018 (includes

corresponding Graph/Chart) III-42

Table 62: European Recent Past, Current & Future Analysisfor Contraceptives by Product Segment - OralContraceptives, Condoms, Implants/Injections and OthersMarkets Independently Analyzed with Annual Sales Figures inUS$ Million for Years 2010 through 2018 (includescorresponding Graph/Chart) III-43

Table 63: European Historic Review for Contraceptives by

Product Segment - Oral Contraceptives, Condoms,

Implants/Injections and Others Markets Segments

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2004 through 2009 (includes corresponding

Graph/Chart) III-44

Table 64: European 15-Year Perspective for Contraceptives byProduct Segment - Percentage Breakdown of Dollar Sales forOral Contraceptives, Condoms, Implants/Injections and OthersMarkets for 2004, 2011 & 2018 (includes correspondingGraph/Chart) III-45

4a. FRANCE III-46

A.Market Analysis III-46

Outlook III-46

Condoms Market III-46

B.Market Analytics III-47

Table 65: French Recent Past, Current & Future Analysis for

Contraceptives by Product Segment - Oral Contraceptives,

Condoms, Implants/Injections and Others Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2010 through 2018 (includes corresponding

Graph/Chart) III-47

Table 66: French Historic Review for Contraceptives byProduct Segment - Oral Contraceptives, Condoms,Implants/Injections and Others Markets SegmentsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2004 through 2009 (includes correspondingGraph/Chart) III-48

Table 67: French 15-Year Perspective for Contraceptives by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Contraceptives, Condoms, Implants/Injections and Others

Markets for 2004, 2011 & 2018 (includes corresponding

Graph/Chart) III-49

4b. GERMANY III-50A.Market Analysis III-50Outlook III-50German Women Record Highest Usage Rate of Contraceptive Pill III-50Condoms Market III-50Key Players III-50B.Market Analytics III-52Table 68: German Recent Past, Current & Future Analysis forContraceptives by Product Segment - Oral Contraceptives,Condoms, Implants/Injections and Others MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-52

Table 69: German Historic Review for Contraceptives by

Product Segment - Oral Contraceptives, Condoms,

Implants/Injections and Others Markets Segments

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2004 through 2009 (includes corresponding

Graph/Chart) III-53

Table 70: German 15-Year Perspective for Contraceptives byProduct Segment - Percentage Breakdown of Dollar Sales forOral Contraceptives, Condoms, Implants/ Injections andOthers Markets for 2004, 2011 & 2018 (includescorresponding Graph/Chart) III-54

4c. ITALY III-55

A.Market Analysis III-55

Outlook III-55

B.Market Analytics III-56

Table 71: Italian Recent Past, Current & Future Analysis

for Contraceptives by Product Segment - Oral

Contraceptives, Condoms, Implants/ Injections and Others

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2010 through 2018 (includes

corresponding Graph/Chart) III-56

Table 72: Italian Historic Review for Contraceptives byProduct Segment - Oral Contraceptives, Condoms,Implants/Injections and Others Markets SegmentsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2004 through 2009 (includes correspondingGraph/Chart) III-57

Table 73: Italian 15-Year Perspective for Contraceptives by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Contraceptives, Condoms, Implants/Injections and Others

Markets for 2004, 2011 & 2018 (includes corresponding

Graph/Chart) III-58

4d. THE UNITED KINGDOM III-59A.Market Analysis III-59Outlook III-59Overview III-59UK Contraceptives Market Sails Through Recession III-59Changing Societal Trends III-60Innovations: Need of the Hour III-60Availability of Contraceptives III-60Contraceptive Injections III-60Emergency Contraception (EC) III-61Barrier Contraceptives III-61Major Trends and Issues III-61Hormone Based Products Overtake Barrier Products III-61Condoms Still Find Immense Favor in Britain III-61Table 74: Condom Usage Trends in the UK (2012): Breakdownof Usage Rate by Age and Gender (includes correspondingGraph/Chart) III-62Value of Condoms Declines Even as Volume Sales Increases III-62Role of Pharmacies in Improving Availability of Condomsand EC Drugs III-62Regulatory Environment III-62CEN Standards III-62Advertising and Promotion III-63Hormone-Based Contraceptives Restricted by Legislation III-63B.Market Analytics III-63Table 75: UK Recent Past, Current & Future Analysis forContraceptives by Product Segment - Oral Contraceptives,Condoms, Implants/Injections and Others MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-63

Table 76: UK Historic Review for Contraceptives by Product

Segment - Oral Contraceptives, Condoms, Implants/Injections

and Others Markets Segments Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2004 through

2009 (includes corresponding Graph/Chart) III-64

Table 77: UK 15-Year Perspective for Contraceptives byProduct Segment - Percentage Breakdown of Dollar Sales forOral Contraceptives, Condoms, Implants/Injections and OthersMarkets for 2004, 2011 & 2018 (includes correspondingGraph/Chart) III-65

4e. SPAIN III-66

A.Market Analysis III-66

Current & Future Analysis III-66

Outlook III-66

B.Market Analytics III-67

Table 78: Spanish Recent Past, Current & Future Analysis for

Contraceptives by Product Segment - Oral Contraceptives,

Condoms, Implants/Injections and Others Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2010 through 2018 (includes corresponding

Graph/Chart) III-67

Table 79: Spanish Historic Review for Contraceptives byProduct Segment - Oral Contraceptives, Condoms,Implants/Injections and Others Markets SegmentsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2004 through 2009 (includes correspondingGraph/Chart) III-68

Table 80: Spanish 15-Year Perspective for Contraceptives by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Contraceptives, Condoms, Implants/Injections and Others

Markets for 2004, 2011 & 2018 (includes corresponding

Graph/Chart) III-69

4f. RUSSIA III-70A.Market Analysis III-70Outlook III-70B.Market Analytics III-71Table 81: Russian Recent Past, Current & Future Analysis forContraceptives by Product Segment - Oral Contraceptives,Condoms, Implants/Injections and Others MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2010 through 2018 (includes correspondingGraph/Chart) III-71

Table 82: Russian Historic Review for Contraceptives by

Product Segment - Oral Contraceptives, Condoms, Implants/

Injections and Others Markets Segments Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2004 through 2009 (includes corresponding Graph/Chart) III-72

Table 83: Russian 15-Year Perspective for Contraceptives byProduct Segment - Percentage Breakdown of Dollar Sales forOral Contraceptives, Condoms, Implants/Injections and OthersMarkets for 2004, 2011 & 2018 (includes correspondingGraph/Chart) III-73

4g. REST OF EUROPE III-74

A.Market Analysis III-74

Outlook III-74

Modern Contraceptives Usage in Eastern European Markets III-74

Table 84: Usage Rates of Modern and Traditional

Contraceptives in Developed and Developing Markets in

Europe (2010) III-75

Regional Briefs

To order this report:Drug and Medication Industry: Global Contraceptives Industry

Contact Clare: [email protected]

US:(339) 368 6001

Intl:+1 339 368 6001

SOURCE Reportlinker